FDAapproval65% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for AstraZeneca.
Regulatory Analysis
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Supporting Context
- Therapeutic area
- Oncology · B-cell Non-Hodgkin Lymphoma
- Sub-indication
- General
Related signal: AstraZeneca Initiates Phase I/II Study of AZD4512 in B-cell Non-Hodgkin Lymphoma